HemoGenix, Inc. (HG), founded in 2000, remains a significant entity in the stem cell assay market. The company has developed proprietary toxicology testing procedures that have been widely utilized by biopharmaceutical companies across the nation for evaluating new drug candidates. Several of these tests have been further refined for internal applications in stem cell and veterinary research, cellular therapy, and regenerative medicine. In 2017, Preferred Cell Systems, Inc. (PCS) was established, accompanied by the launch of the website www.preferred-cell-systems.com. This initiative aims to enhance education, product development, and marketing of advanced testing kits and assays. With the global emphasis on reliable testing platforms, HG/PCS is well-positioned for new ownership that can leverage its long-established industry relationships to expand contract services and scale the distribution of its diverse array of developed kits and assays. The growth potential is evidenced by a 200% increase in kit assay sales in 2024, driving gross revenue close to $1 million. Early in 2024, the owner appointed a full-time lab manager to facilitate the transition of daily operations from the founder. The owner seeks to fully retire but is open to consulting for a negotiated period to ensure a successful transition.